An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies — Stella
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations(1 site)
China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei